Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23


Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.

Tariq R, Singh S, Gupta A, Pardi DS, Khanna S.

JAMA Intern Med. 2017 Jun 1;177(6):784-791. doi: 10.1001/jamainternmed.2017.0212. Review.


Widespread use of gastric acid inhibitors in infants: Are they needed? Are they safe?

Safe M, Chan WH, Leach ST, Sutton L, Lui K, Krishnan U.

World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):531-539. Review.


Proton Pump Inhibitors and Clostridium Difficile Infection: Are We Propagating an Already Rapidly Growing Healthcare Problem?

Patil R, Blankenship L.

Gastroenterology Res. 2013 Oct;6(5):171-173. Epub 2013 Oct 31. Review.


Assessing the Risk of Hospital-Acquired Clostridium Difficile Infection With Proton Pump Inhibitor Use: A Meta-Analysis.

Arriola V, Tischendorf J, Musuuza J, Barker A, Rozelle JW, Safdar N.

Infect Control Hosp Epidemiol. 2016 Dec;37(12):1408-1417. Epub 2016 Sep 28.


Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital.

Hikone M, Ainoda Y, Tago S, Fujita T, Hirai Y, Takeuchi K, Totsuka K.

Clin Exp Gastroenterol. 2015 Jul 14;8:191-6. doi: 10.2147/CEG.S85007. eCollection 2015.


Hospitalization Type and Subsequent Severe Sepsis.

Prescott HC, Dickson RP, Rogers MA, Langa KM, Iwashyna TJ.

Am J Respir Crit Care Med. 2015 Sep 1;192(5):581-8. doi: 10.1164/rccm.201503-0483OC.


Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility.

Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK.

Microbiome. 2014 Nov 25;2:42. doi: 10.1186/2049-2618-2-42. eCollection 2014. Erratum in: Microbiome. 2016;4:10.


Risk Factors for Delayed Recurrence of Clostridium difficile Infection.

Kim JW.

Intest Res. 2014 Oct;12(4):266-7. doi: 10.5217/ir.2014.12.4.266. Epub 2014 Oct 27. No abstract available.


Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study.

Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER.

BMC Infect Dis. 2014 Jun 4;14:306. doi: 10.1186/1471-2334-14-306.


Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review.

Abou Chakra CN, Pepin J, Sirard S, Valiquette L.

PLoS One. 2014 Jun 4;9(6):e98400. doi: 10.1371/journal.pone.0098400. eCollection 2014. Review. Erratum in: PLoS One. 2014;9(8):e107420.


Clostridium difficile infection: management strategies for a difficult disease.

Khanna S, Pardi DS.

Therap Adv Gastroenterol. 2014 Mar;7(2):72-86. doi: 10.1177/1756283X13508519. Review.


Parameters for the mathematical modelling of Clostridium difficile acquisition and transmission: a systematic review.

Otete EH, Ahankari AS, Jones H, Bolton KJ, Jordan CW, Boswell TC, Wilcox MH, Ferguson NM, Beck CR, Puleston RL.

PLoS One. 2013 Dec 20;8(12):e84224. doi: 10.1371/journal.pone.0084224. eCollection 2013. Review.


Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges.

Lim YJ, Chun HJ.

Gastroenterol Res Pract. 2013;2013:761060. doi: 10.1155/2013/761060. Epub 2013 Sep 12. Review.


Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients.

Freedberg DE, Salmasian H, Friedman C, Abrams JA.

Am J Gastroenterol. 2013 Nov;108(11):1794-801. doi: 10.1038/ajg.2013.333. Epub 2013 Sep 24.


Nutritional protective mechanisms against gut inflammation.

Viladomiu M, Hontecillas R, Yuan L, Lu P, Bassaganya-Riera J.

J Nutr Biochem. 2013 Jun;24(6):929-39. doi: 10.1016/j.jnutbio.2013.01.006. Epub 2013 Mar 27. Review.


Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile.

Viladomiu M, Hontecillas R, Pedragosa M, Carbo A, Hoops S, Michalak P, Michalak K, Guerrant RL, Roche JK, Warren CA, Bassaganya-Riera J.

PLoS One. 2012;7(10):e47525. doi: 10.1371/journal.pone.0047525. Epub 2012 Oct 11.


Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study.

Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS.

Mayo Clin Proc. 2012 Jul;87(7):636-42. doi: 10.1016/j.mayocp.2011.12.021.


Predictors of first recurrence of Clostridium difficile infection: implications for initial management.

Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, O'Connor L, Vaughan A, Crook DW, Wilcox MH, Peto TE; Infections in Oxfordshire Research Database.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S77-87. doi: 10.1093/cid/cis356.


Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases.

Oka K, Osaki T, Hanawa T, Kurata S, Okazaki M, Manzoku T, Takahashi M, Tanaka M, Taguchi H, Watanabe T, Inamatsu T, Kamiya S.

J Clin Microbiol. 2012 Mar;50(3):915-21. doi: 10.1128/JCM.05588-11. Epub 2012 Jan 11.


Clostridium difficile Infection and Proton Pump Inhibitor Use in Hospitalized Pediatric Cystic Fibrosis Patients.

Pohl JF, Patel R, Zobell JT, Lin E, Korgenski EK, Crowell K, Mackay MW, Richman A, Larsen C, Chatfield BA.

Gastroenterol Res Pract. 2011;2011:345012. doi: 10.1155/2011/345012. Epub 2011 Nov 15.

Supplemental Content

Support Center